2. Search Result
Search Result
Results for "

abnormal kinase

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148066
    DB0662

    		Others Others
    DB0662 is a compound for kinase-targeted protein degradation and can be used in studies of diseases mediated by abnormal kinase activity, as well as for the identification of degradable kinases and optimal kinases .
    DB0662
  • HY-145601
    Tinengotinib

    TT 00420

    		 Aurora Kinase VEGFR Cancer
    Tinengotinib is the modulator of one or more protein kinases such as Aurora kinase and VEGFR kinase. Tinengotinib has the potential for the research of these kinase abnormalities diseases mediated, especially cancer-related diseases (extracted from patent WO2018108079A1) .
    Tinengotinib
  • HY-103032
    Multi-kinase inhibitor 1

    		PDGFR c-Kit Bcr-Abl Cancer
    Multi-kinase inhibitor 1 is a potent multi-kinase inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl .
    Multi-kinase inhibitor 1
  • HY-153227
    SU 5616

    		c-Met/HGFR Cancer
    SU 5616 is an organic compound. SU 5616 potentially modulates tyrosine kinase signal transduction, and regulates abnormal cell proliferation .
    SU 5616
  • HY-152247
    DDO3711

    		MAP3K Cancer
    DDO3711, a PP5-recruiting phosphatase recruitment chimeras (PHORCs), is formed by connecting a small molecular apoptosis signal-regulated kinase 1 (ASK1) inhibitor to a PP5 activator through a chemical linker. DDO3711 specifically inhibits ASK1 (IC50 =164.1 nM) not ASK2 (IC50>20 μM). DDO3711 significantly dephosphorylates p-ASK1 T838 by recruiting PP5 and shows the ASK1-dependent antiproliferative activity. DDO3711 has anti-cancer activity and has the potential for abnormally phosphorylated oncoproteins research .
    DDO3711
  • HY-10971A
    Alisertib sodium

    MLN 8237 sodium

    		 Aurora Kinase Autophagy Apoptosis Cancer
    Alisertib (MLN 8237) sodium is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib sodium induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .
    Alisertib sodium
  • HY-101837
    CGP 53716

    		Others Inflammation/Immunology
    CGP 53716 is a potent protein tyrosine kinase inhibitor. CGP 53716 has selective activity of platelet-derived growth factor (PDGF) receptor. CGP 53716 can be used in the study of disease induced by abnormal cell proliferation induced by PDGF receptor activation .
    CGP 53716
  • HY-10971
    Alisertib
    Maximum Cited Publications
    38 Publications Verification

    MLN 8237

    		 Aurora Kinase Autophagy Apoptosis Cancer
    Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .
    Alisertib
  • HY-124042
    K6PC-5
    1 Publications Verification

    		 SphK Filovirus Infection Neurological Disease Inflammation/Immunology
    K6PC-5, a ceramide derivative, is a sphingosine kinase 1(SPHK1) activator and elicites a rapid transient increase in intracellular calcium levels. K6PC-5 has the potential for skin diseases involving abnormal keratinocyte, and neurodegeneration and virus infection research .
    K6PC-5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: